Pachychoroid-Phenotype Effects of Anti-VEGF Monotherapy in P
A Study was conducted to investigate whether the efficacy of anti-vascular endothelial growth factor (VEGF) monotherapy for polypoidal choroidal vasculopathy (PCV) differs between pachychoroid and non-pachychoroid phenotypes in the long term.

This study included 115 eyes in 115 consecutive patients with symptomatic PCV who were treated with anti-VEGF monotherapy. Eligible eyes were assigned to either a pachy-PCV group, with a pachychoroid phenotype, or a non-pachy-PCV group, without a pachychoroid phenotype. Best-corrected visual acuity (BCVA) and other parameters over a 5-year period were compared between the groups.

--48 eyes and 67 eyes were classified into the pachy-PCV and non-pachy-PCV groups respectively.

--Baseline and 5-year BCVA were 0.19 ± 0.20 and 0.16 ± 0.28 in the pachy-PCV group, respectively, and 0.25 ± 0.26 and 0.26 ± 0.36 in the non-pachy-PCV group respectively.

--BCVA did not change significantly in either group.

--BCVA did not differ between the groups at any observation time-point.

--Subfoveal choroidal thickness (SFCT) at baseline and at 5 years was significantly higher in the pachy-PCV group than in the non-pachy-PCV group; however, the mean rate of decrease in SFCT did not differ in either group over the 5-year period.

Conclusively, study suggest that anti-VEGF monotherapy was similarly effective for pachychoroid- and non-pachychoroid-phenotype eyes with PCV.